With $277 Million In New Funding, This Startup Hopes To Unlock The Secrets Of Biology
Summary
Trying to understand the secret of life and making precision medicine accessible and affordableits an expensive business, CEO and Founder Molly He told Forbes, noting the new investment will help accelerate the advance and commercialization of its work. The company is on track to more than double that in 2024 from sales of its $289,000 machines and the biological analysis kits it develops for them.Despite its growth, Element still faces a 800-pound gorilla in the lab: Illumina, which currently controls about 80% of the sequencing market. According to a paper published in the journal Nature Biotechnology last year, this method produces highly accurate results using a simpler workflow and fewer materials. If you only need to go two miles, youve burned the same amount of gas, he said.Molly He, 53, first came to the United States in 1992, immigrating from China to UCLA to pursue her PhD in protein biophysics and biochemistry. Machine learning is already deployed in its products as part of the genome sequencing process, but He said additional development is needed as Elements customers gather more and different types of data.I call this an investment in scientific freedom, she said.